Varian Medical Systems — Merger or Acquisition (January 2018)
10 slides from Varian Medical Systems's merger presentation, Jan 30, 2018
Slide 1: Acquisition of Sirtex
Dow Wilson President and Chief Executive Officer January 30, 2018 Acquisition of SIRTeX
Slide 2: Forward-Looking Statements
This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. 2 Forward - Looking Statements Except for historical information, this presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1
Slide 3: Deal summary
Deal summary • Builds on our foundation as a global leader in radiation medicine • Adds platform to enter fast - growing interventional oncology market • Extends our oncology customer base to accelerate revenue • Leverages our global operations, treatment planning, oncology practice management softw
Slide 4: Long-term growth and value creation strategy
Long - term growth and value creation strategy 4 Global Leader in Radiation Therapy Radiation oncology OIS Radiosurgery Brachytherapy Radiation oncology treatment planning Proton therapy Radiation therapy Global Leader of Multi - Disciplinary, Integrated Cancer Care Solutions Interventional oncology
Slide 5: Interventional oncology: $1B market by 2022
Interventional oncology … $1B market by 2022 Expands our ability to help cancer patients 5 Global Leader of Multi - Disciplinary, Integrated Cancer Care Solutions Interventional oncology Surgical oncology Diagnostic imaging Radiation oncology Precision medicine Medical oncology Generate insights Cal
Slide 6: Sirtex Medical Limited: company overview
SIRTeX Medical Limited: company overview ASX:SRX / HQ: Sydney, Australia 6 • Australian headquartered, global healthcare business • Listed on the ASX since 2000 (ASX:SRX); S&P / ASX 200 Index • Focus on Interventional Oncology Market – a rapidly growing subset of the cancer market that utilizes mini
Slide 7: Deal rationale: Acquire platform to build new interventional oncology business unit
Deal rationale Acquire platform to build new interventional oncology business unit 7 • Adds global leader in radioembolization to our cancer care portfolio − Extends into adjacent market with proven technology, products, and services; enhances current position in cancer centers − Adds established an
Slide 8: Sirtex Medical Limited: financial overview
SIRTeX Medical Limited: financial overview 80%+ gross margin, consumables business model 8 • Sales geographic breakdown: 80% USA, 16% EMEA and 4% APAC • 13 consecutive years of dose sales growth • 80%+ gross margin over last 5 years • 21.5% compound annual growth in sales over 10 years • Highly prof
Slide 9: Deal terms
Deal terms Incremental revenue growth, margins and earnings • Purchase price − A$28 / share (US$1,283M equity value) − Financed with a combination of cash and debt facilities • Financial impact − Accretive to non - GAAP earnings per share by 5 - 6% in the first full fiscal year after closing the tra
Slide 10: Our promise: People powering victories
Our promise 10 People powering victories Imagine a world without fear of cancer. We do, every day. We innovate new technologies for treating cancer and for connecting clinical teams to advance patient outcomes. Through ingenuity we inspire new victories and empower people in the fight against cancer